亚洲非瓣膜性房颤患者口服抗凝药的有效性与安全性
结果显示所有NOAC较华法林均降低缺血性卒中、颅内出血、消化道出血、大出血及复合终点风险,且NOAC间存在差异。
要点
- 所有NOAC较华法林降低缺血性卒中、颅内出血、消化道出血、大出血及复合终点风险。
- 阿哌沙班和艾多沙班较利伐沙班和达比加群降低缺血性卒中发生率。
- 阿哌沙班、达比加群和艾多沙班较利伐沙班降低消化道出血和大出血发生率。
核心结论
- 在亚洲非瓣膜性房颤患者中,四种NOAC较华法林均降低缺血性卒中和主要出血风险。
- NOAC间临床结局存在差异,可为个体化选药提供参考。
研究设计与样本
- 回顾性非随机观察性队列研究,基于韩国健康保险审查与评估数据库。
- 采用逆概率治疗加权平衡比较队列。
主要发现
- 与华法林相比,所有NOAC均与更低的缺血性卒中、颅内出血、消化道出血、大出血及复合终点风险相关。
- 阿哌沙班和艾多沙班的缺血性卒中发生率低于利伐沙班和达比加群。
- 阿哌沙班、达比加群和艾多沙班的消化道出血及大出血发生率低于利伐沙班。
- 阿哌沙班与艾多沙班的复合临床终点差异无统计学意义。
临床怎么用
- 亚洲非瓣膜性房颤患者优先考虑NOAC而非华法林以降低卒中和出血风险。
- 可根据患者卒中与出血风险特征选择NOAC种类,如高卒中风险可考虑阿哌沙班或艾多沙班。
局限性
- 回顾性非随机观察性设计,可能存在残余混杂。
- 基于韩国人群数据,外推至其他亚洲人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Limited evidence exists on the effectiveness and safety of warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from current clinical practice in the Asian population with nonvalvular atrial fibrillation. We aimed to evaluate the comparative effectiveness and safety of warfarin and 4 NOACs. Methods- We studied a retrospective nonrandomized observational cohort of oral anticoagulant naïve nonvalvular patients with atrial fibrillation treated with warfarin or NOACs (rivaroxaban, dabigatran, apixaban, or edoxaban) from January 2015 to December 2017, based on the Korean Health Insurance Review and Assessment database. For the comparisons, warfarin to 4 NOACs and NOAC to NOAC comparison cohorts were balanced using the inverse probability of treatment weighting. Ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, and a composite clinical outcome were evaluated. Results- A total of 116 804 patients were included (25 420 with warfarin, 35 965 with rivaroxaban, 17 745 with dabigatran, 22 177 with apixaban, and 15 496 with edoxaban). Compared with warfarin, all NOACs were associated with lower risks of ischemic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, and composite outcome. Apixaban and edoxaban showed a lower rate of ischemic stroke compared with rivaroxaban and dabigatran. Apixaban, dabigatran, and edoxaban had a lower rate of gastrointestinal bleeding and major bleeding compared with rivaroxaban. The composite clinical outcome was nonsignificantly different for apixaban versus edoxaban. Conclusions- In this large contemporary nonrandomized Asian cohort, all 4 NOACs were associated with lower rates of ischemic stroke and major bleeding compared with warfarin. Differences in clinical outcomes between NOACs may give useful guidance for physicians to choose drugs to fit their particular patient clinical profile.
引用
- Lee SR, Choi EK, Kwon S, et al. Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation. Stroke. 2019. PMID: 31208303. doi:10.1161/STROKEAHA.119.025536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。